Compare Icl Group Ltd (ICL) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Inovio Pharmaceuticals Inc — how do they compare? Icl Group Ltd trades at $5.47 (market cap $6.94B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Icl Group Ltd is far larger — about 88.4× Inovio Pharmaceuticals Inc's market cap, and Icl Group Ltd pays a 3.86% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ICL | INO | |
|---|---|---|
Market Cap | $6.94B | $78.55M |
Sector | Basic Materials | Health |
52-Week High | $6.84 | $2.87 |
52-Week Low | $4.80 | $0.66 |
Enterprise Value | $9.58B | $49.56M |
Dividend Yield | 3.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.455, up 2.15% today, with a bullish technical signal from moving averages. The company reported Q2 2026 earnings of $0.12 per share, beating estimates, and announced a cost-transformation program. Revenue for 2025 was $7.15 billion, with a net income margin of 3.95%. The stock has a P/E ratio of 22.25 and an EV/EBITDA of 7.02.
Outlook is mixed; earnings beats and operational improvements support upside, but analyst consensus is entirely Hold, reflecting valuation concerns. Key risks include raw material cost volatility and foreign exchange headwinds. The stock offers a dividend yield but faces margin pressure from declining profitability trends.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
